Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2011, Article ID 271321, 10 pages
http://dx.doi.org/10.1155/2011/271321
Research Article

The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis

1Medical Affairs, Teva Pharmaceuticals, 901 East 104th Street, Suite 900, Kansas City, MO 64131, USA
2HealthMetrics Outcomes Research, 120 Anchorage Circle, Groton, CT 06340, USA

Received 3 November 2010; Revised 7 March 2011; Accepted 29 April 2011

Academic Editor: Peter Arnett

Copyright © 2011 M. Tarrants et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Courtney, K. Treadaway, G. Remington, and E. Frohman, “Multiple sclerosis,” Medical Clinics of North America, vol. 93, no. 2, pp. 451–476, ix-x, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. National Multiple Sclerosis Society, “FAQs about MS: National MS Society,” 2009, http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/FAQs-about-MS/index.aspx#howmany. View at Google Scholar
  3. H. Naci, R. Fleurence, J. Birt, and A. Duhig, “Economic burden of multiple sclerosis: a systematic review of the literature,” PharmacoEconomics, vol. 28, no. 5, pp. 363–379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. O'Brien, A. J. Ward, A. R. Patrick, and J. Caro, “Cost of managing an episode of relapse in multiple sclerosis in the United States,” BMC Health Services Research, vol. 3, no. 1, p. 17, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. Prescott, S. Factor, M. Pill, and G. W. Levi, “Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database,” Journal of Managed Care Pharmacy, vol. 13, no. 1, pp. 44–52, 2007. View at Google Scholar · View at Scopus
  6. K. Whetten-Goldstein, F. A. Sloan, L. B. Goldstein, and E. D. Kulas, “A comprehensive assessment of the cost of multiple sclerosis in the United States,” Multiple Sclerosis, vol. 4, no. 5, pp. 419–425, 1998. View at Google Scholar · View at Scopus
  7. National Multiple Sclerosis Society, “Multiple Sclerosis: Just the Facts,” 2009, http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/what-is-ms/index.aspx. View at Google Scholar
  8. M. J. Tullman, F. D. Lublin, and A. E. Miller, “Immunotherapy of multiple sclerosis—current practice and future directions,” Journal of Rehabilitation Research and Development, vol. 39, no. 2, pp. 273–285, 2002. View at Google Scholar · View at Scopus
  9. C. Van Houtven, M. Weinberger, and T. Carey, “Implications of nonadherence for economic evaluation and health policy,” in Patient Treatment Adherence: Concepts, Interventions, and Measurement, pp. 421–451, Routledge, London, UK, 2005. View at Google Scholar
  10. J. M. Bruce, L. M. Hancock, P. Arnett, and S. Lynch, “Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition,” Journal of Behavioral Medicine, vol. 33, no. 3, pp. 219–227, 2010. View at Google Scholar
  11. J. M. Bruce, L. M. Hancock, and S. G. Lynch, “Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report,” Multiple Sclerosis, vol. 16, no. 1, pp. 112–120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Lugaresi, “Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?” Expert Opinion on Drug Delivery, vol. 6, no. 9, pp. 995–1002, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Treadaway, G. Cutter, A. Salter et al., “Factors that influence adherence with disease-modifying therapy in MS,” Journal of Neurology, vol. 256, no. 4, pp. 568–576, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. R. A. Marrie, R. Horwitz, G. Cutter, T. Tyry, D. Campagnolo, and T. Vollmer, “The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated,” Multiple Sclerosis, vol. 15, no. 3, pp. 385–392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. D. Sadovnick, R. A. Remick, J. Allen et al., “Depression and multiple sclerosis,” Neurology, vol. 46, no. 3, pp. 628–632, 1996. View at Google Scholar · View at Scopus
  16. R. B. Schiffer and H. B. Babigian, “Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis: an epidemiologic study,” Archives of Neurology, vol. 41, no. 10, pp. 1067–1069, 1984. View at Google Scholar · View at Scopus
  17. J. I. Ivanova, H. G. Birnbaum, Y. Kidolezi, G. Subramanian, S. A. Khan, and M. D. Stensland, “Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder,” Current Medical Research and Opinion, vol. 26, no. 10, pp. 2475–2484, 2010. View at Publisher · View at Google Scholar
  18. K. Lang, J. L. Meyers, J. R. Korn et al., “Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics,” Psychiatric Services, vol. 61, no. 12, pp. 1239–1247, 2010. View at Publisher · View at Google Scholar
  19. A. Qaseem, V. Snow, T. D. Denberg, M. A. Forciea, and D. K. Owens, “Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians,” Annals of Internal Medicine, vol. 149, no. 10, pp. 725–733, 2008. View at Google Scholar · View at Scopus
  20. J. A. Cramer, A. Roy, A. Burrell et al., “Medication compliance and persistence: terminology and definitions,” Value in Health, vol. 11, no. 1, pp. 44–47, 2008. View at Publisher · View at Google Scholar
  21. J. Cooper, L. Hall, A. Penland, A. Krueger, and J. May, “Measuring medication adherence,” Population Health Management, vol. 12, no. 1, pp. 25–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. I. Ivanova, H. G. Birnbaum, M. Hsieh et al., “Adherence to inhaled corticosteroid use and local adverse events in persistent asthma,” The American Journal of Managed Care, vol. 14, no. 12, pp. 801–809, 2008. View at Google Scholar · View at Scopus
  23. B. C. Martin, E. K. Wiley-Exley, S. Richards, M. E. Domino, T. S. Carey, and B. L. Sleath, “Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication,” Annals of Pharmacotherapy, vol. 43, no. 1, pp. 36–44, 2009. View at Publisher · View at Google Scholar
  24. H. Florez, J. Luo, S. Castillo-Florez et al., “Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes,” Postgraduate Medicine, vol. 122, no. 2, pp. 112–120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. R. L. Sedjo and S. Devine, “Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer,” Breast Cancer Research and Treatment, vol. 125, no. 1, pp. 191–200, 2011. View at Publisher · View at Google Scholar
  26. W. D'Hoore, C. Sicotte, and C. Tilquin, “Risk adjustment in outcome assessment: the Charlson comorbidity index,” Methods of Information in Medicine, vol. 32, no. 5, pp. 382–387, 1993. View at Google Scholar
  27. R. A. Deyo, D. C. Cherkin, and M. A. Ciol, “Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases,” Journal of Clinical Epidemiology, vol. 45, no. 6, pp. 613–619, 1992. View at Publisher · View at Google Scholar
  28. V. Sundararajan, H. Quan, P. Halfan et al., “Cross-national comparative performance of three versions of the ICD-10 Charlson index,” Medical Care, vol. 45, no. 12, pp. 1210–1215, 2007. View at Publisher · View at Google Scholar
  29. L. Chan, A. Shumway-Cook, K. M. Yorkston, M. A. Ciol, B. J. Dudgeon, and J. M. Hoffman, “Design and validation of a methodology using the International Classification of Diseases, 9th Revision, to identify secondary conditions in people with disabilities,” Archives of Physical Medicine and Rehabilitation, vol. 86, no. 5, pp. 1065–1069, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. M. de Groot, R. Anderson, K. E. Freedland, R. E. Clouse, and P. J. Lustman, “Association of depression and diabetes complications: a meta-analysis,” Psychosomatic Medicine, vol. 63, no. 4, pp. 619–630, 2001. View at Google Scholar · View at Scopus
  31. J. C. Barefoot, B. H. Brummett, M. J. Helms, D. B. Mark, I. C. Siegler, and R. B. Williams, “Depressive symptoms and survival of patients with coronary artery disease,” Psychosomatic Medicine, vol. 62, no. 6, pp. 790–795, 2000. View at Google Scholar · View at Scopus
  32. M. M. Burg, M. C. Benedetto, and R. Soufer, “Depressive symptoms and mortality two years after coronary artery bypass graft surgery (CABG) in men,” Psychosomatic Medicine, vol. 65, no. 4, pp. 508–510, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Frasure-Smith and F. Lespérance, “Depression and other psychological risks following myocardial infarction,” Archives of General Psychiatry, vol. 60, no. 6, pp. 627–636, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. M. W. Kaufmann, J. P. Fitzgibbons, E. J. Sussman et al., “Relation between myocardial infarction, depression, hostility, and death,” The American Heart Journal, vol. 138, no. 3, part 1, pp. 549–554, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. K. H. Ladwig, M. Kieser, J. König, G. Breithardt, and M. Borggrefe, “Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study,” The European Heart Journal, vol. 12, no. 9, pp. 959–964, 1991. View at Google Scholar · View at Scopus
  36. F. Lespérance, N. Frasure-Smith, M. Juneau, and P. Théroux, “Depression and 1-year prognosis in unstable angina,” Archives of Internal Medicine, vol. 160, no. 9, pp. 1354–1360, 2000. View at Google Scholar · View at Scopus
  37. F. Lespérance, N. Frasure-Smith, M. Talajic, and M. G. Bourassa, “Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction,” Circulation, vol. 105, no. 9, pp. 1049–1053, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. C. M. Eze-Nliam, B. D. Thombs, B. B. Lima, C. G. Smith, and R. C. Ziegelstein, “The association of depression with adherence to antihypertensive medications: a systematic review,” Journal of Hypertension, vol. 28, no. 9, pp. 1785–1795, 2010. View at Google Scholar
  39. J. B. Garner, “Problems of nonadherence in cardiology and proposals to improve outcomes,” The American Journal of Cardiology, vol. 105, no. 10, pp. 1495–1501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Gehi, D. Haas, S. Pipkin, and M. A. Whooley, “Depression and medication adherence in outpatients with coronary heart disease,” Archives of Internal Medicine, vol. 165, no. 21, pp. 2508–2513, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Abrahamian, P. Hofmann, R. Prager, and H. Toplak, “Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group),” Neuropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 261–266, 2009. View at Google Scholar · View at Scopus